Has been trading around 30c since the poor half yearly (m/c = $16m), a fair way back from $2.75 it reached a few years ago.

While FY13 will be a bit of a transition year, FY14 should be a significant improvement, particularly with the benefits of the improved ASP plant as per below.

"The upgrade and re‐establishment of the ADP Protein Plant remains on schedule with the construction phasecompleted and with plant commissioning underway. The commencement of commercial operation isscheduled for the beginning of the June quarter this year. The directors remain confident that the previouslyreleased forecasts for ADP of EBITDA of $1.8 million in the first full year of operation increasing to $4 millionin future years, will be met. With a total investment in excess of $18 million, the directors believe this plantwill deliver consistent, strong financial returns and provide the foundation for a pipeline of innovation,research and product development centred around a range of dairy proteins and their therapeuticapplications. "